ArticlePflugers Archiv : European journal of physiology2019
Butyric acid, a gut bacteria metabolite, lowers arterial blood pressure via colon-vagus nerve signaling and GPR41/43 receptors.
Article in Pflugers Archiv : European journal of physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Exploring the research progression and evolutionary trends of gut microbiome and hypertension: a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study.BMC medicine · 2022Pooled it
- Trial
- Trial
- Increases in Circulating and Fecal Butyrate are Associated With Reduced Blood Pressure and Hypertension: Results From the SPIRIT Trial.Journal of the American Heart Association · 2022Trial
- Review
- Gut microbiota‑derived metabolites in cardiovascular disease: Focus on trimethylamine N‑oxide, short‑chain fatty acids and bile acids (Review).Molecular medicine reports · 2026Review
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue.Endocrinology, diabetes & metabolism · 2026Review
- Gut-bone axis crosstalk: Microbiota-driven immune-metabolic-neural networks in bone disorders and precision interventions.Journal of orthopaedic translation · 2026Review
- Gut Microbiota and Short-Chain Fatty Acids in Cardiometabolic HFpEF: Mechanistic Pathways and Nutritional Therapeutic Perspectives.Nutrients · 2026Review
- Metabolomic Profiling of Long-Lived Individuals Reveals a Distinct Subgroup with Cardiovascular Disease and Elevated Butyric Acid Derivatives.Metabolites · 2025Article
- Acetate concentration correlates with MSNA in patients with resistant hypertension.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Article
- Review
- Postbiotics: A Promising Approach to Combat Age-Related Diseases.Life (Basel, Switzerland) · 2025Review
- Pectin and Its Beneficial Effect on Health: New Contributions in Research and the Need to Increase Fruits and Vegetables Consumption-A Review.International journal of molecular sciences · 2025Review
- Association between the gut microbiotic composition and dietary patterns in hypertensive elderly patients: a cross-sectional study.Nutrition & metabolism · 2025Article
- The association between the gut microbiome and 24-h blood pressure measurements in the SCAPIS study.Communications medicine · 2025Article
- Microbiota in Gut-Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease.Comprehensive physiology · 2025Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Butyric acid (BA) is a short-chain fatty acid (SCFA) produced by gut bacteria in the colon. We hypothesized that colon-derived BA may affect hemodynamics. Arterial blood pressure (BP) and heart rate (HR) were recorded in anesthetized, male, 14-week-old Wistar rats. A vehicle, BA, or 3-hydroxybutyrate, an antagonist of SCFA receptors GPR41/43 (ANT) were administered intravenously (IV) or into the colon (IC). Reactivity of mesenteric (MA) and gracilis muscle (GMA) arteries was tested ex vivo. The concentration of BA in stools, urine, portal, and systemic blood was measured with liquid chromatography coupled with mass spectrometry. BA administered IV decreased BP with no significant effect on HR. The ANT reduced, whereas L-NAME, a nitric oxide synthase inhibitor, did not affect the hypotensive effect of BA. In comparison to BA administered intravenously, BA administered into the colon produced a significantly longer decrease in BP and a decrease in HR, which was associated with a 2-3-fold increase in BA colon content. Subphrenic vagotomy and IC pretreatment with the ANT significantly reduced the hypotensive effect. Ex vivo, BA dilated MA and GMA. In conclusion, an increase in the concentration of BA in the colon produces a significant hypotensive effect which depends on the afferent colonic vagus nerve signaling and GPR41/43 receptors. BA seems to be one of mediators between gut microbiota and the circulatory system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.